NTLA vs. ACLX, SWTX, RARE, AKRO, VKTX, IMVT, ALVO, RYTM, MRUS, and CRNX
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Immunovant (IMVT), Alvotech (ALVO), Rhythm Pharmaceuticals (RYTM), Merus (MRUS), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Intellia Therapeutics vs.
Intellia Therapeutics (NASDAQ:NTLA) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
In the previous week, Intellia Therapeutics had 26 more articles in the media than Arcellx. MarketBeat recorded 34 mentions for Intellia Therapeutics and 8 mentions for Arcellx. Arcellx's average media sentiment score of 0.74 beat Intellia Therapeutics' score of 0.24 indicating that Arcellx is being referred to more favorably in the news media.
Intellia Therapeutics currently has a consensus target price of $37.56, suggesting a potential upside of 303.39%. Arcellx has a consensus target price of $108.46, suggesting a potential upside of 49.64%. Given Intellia Therapeutics' higher possible upside, research analysts clearly believe Intellia Therapeutics is more favorable than Arcellx.
Arcellx has higher revenue and earnings than Intellia Therapeutics. Arcellx is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Intellia Therapeutics' return on equity.
88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 3.2% of Intellia Therapeutics shares are held by insiders. Comparatively, 6.2% of Arcellx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Intellia Therapeutics received 375 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 68.90% of users gave Intellia Therapeutics an outperform vote.
Intellia Therapeutics has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Summary
Arcellx beats Intellia Therapeutics on 13 of the 19 factors compared between the two stocks.
Get Intellia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NTLA) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy NTLA Stock Free NTLA Stock Alerts